What admission orders should be placed for a patient with community-acquired pneumonia?

Admission Orders for Community-Acquired Pneumonia

For patients admitted with CAP, immediately initiate empirical antibiotic therapy with a β-lactam (ceftriaxone 1-2g IV daily, cefotaxime, or ampicillin-sulbactam) plus either azithromycin 500mg IV daily or a respiratory fluoroquinolone (levofloxacin 750mg IV daily or moxifloxacin 400mg IV daily), with the first dose administered in the emergency department before transfer to the floor 1, 2.

Essential Admission Orders

Immediate Antibiotic Therapy

• Standard CAP (non-ICU): β-lactam + macrolide OR respiratory fluoroquinolone alone

  • Ceftriaxone 1-2g IV q24h PLUS azithromycin 500mg IV q24h (preferred combination) 1, 2
  • Alternative: Levofloxacin 750mg IV q24h as monotherapy
  • Penicillin allergy: Respiratory fluoroquinolone + aztreonam 1

• Severe CAP (ICU patients): β-lactam + (azithromycin OR fluoroquinolone)

  • Ceftriaxone 2g IV q24h (or cefotaxime) PLUS azithromycin 500mg IV q24h 1
  • OR β-lactam PLUS levofloxacin 750mg IV q24h 1

Diagnostic Studies

• Chest X-ray (if not already done) 2
• Blood cultures x2 before antibiotics 1
• Arterial blood gas or pulse oximetry 1, 2
• Complete blood count with differential 2
• Basic metabolic panel 2
• COVID-19 and influenza testing when these viruses are circulating in the community 2
• Urinary antigen testing for S. pneumoniae and Legionella in severe cases or ICU admissions 1

Supportive Care Orders

• Oxygen therapy to maintain SpO₂ ≥90% 1
• IV fluids for hydration and hemodynamic support as needed
• Vital signs every 4 hours initially
• Respiratory rate monitoring (tachypnea >30/min is a key severity indicator) 1

Special Considerations for Severe CAP

If hypotensive despite fluid resuscitation:

• Screen for adrenal insufficiency 1
• Consider stress-dose corticosteroids (hydrocortisone 50mg IV q6h or equivalent) within 24 hours of severe CAP presentation 1, 2
• Systemic corticosteroids may reduce 28-day mortality in severe CAP 2

If Pseudomonas risk factors present (structural lung disease, recent antibiotics, recent hospitalization):

• Upgrade to antipseudomonal β-lactam (piperacillin-tazobactam 4.5g IV q6h, cefepime, imipenem, or meropenem) PLUS ciprofloxacin or levofloxacin 750mg 1

If MRSA risk factors present (recent influenza, IV drug use, known colonization):

• Add vancomycin 15-20mg/kg IV q8-12h (target trough 15-20) OR linezolid 600mg IV q12h 1

Transition and Duration Planning

IV to Oral Switch Criteria

Switch to oral antibiotics when the patient meets ALL of the following 1:

• Hemodynamically stable
• Clinically improving
• Afebrile for 48-72 hours
• Able to take oral medications
• Functioning GI tract
• No more than 1 CAP-associated sign of clinical instability

Minimum Treatment Duration

• Minimum 5 days of therapy (not 7-10 days as traditionally taught) 1
• Must be afebrile 48-72 hours before discontinuation 1
• Must have ≤1 clinical instability sign at discontinuation 1
• Longer duration needed if initial therapy was inactive against identified pathogen or if complicated by extrapulmonary infection 1

The 2024 JAMA review confirms that hospitalized patients without resistant bacteria risk factors can be treated with β-lactam/macrolide combination for a minimum of 3 days, though the IDSA/ATS guideline recommends 5 days as the standard 2, 1. The most recent 2025 ATS guideline 3 and 2023 European guidelines 4 support shorter durations when clinical stability is achieved.

Critical Pitfalls to Avoid

• Do not delay antibiotics: First dose must be given in the ED, not after admission 1
• Do not use macrolide monotherapy for hospitalized patients due to resistance concerns 1
• Do not continue IV antibiotics once oral switch criteria are met—inpatient observation on oral therapy is unnecessary 1
• Do not automatically treat for 7-10 days—this is outdated; 5 days minimum with clinical stability is sufficient 1
• Do not forget to test for influenza and COVID-19 when prevalent, as this changes management 2